Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

The study will evaluate a 7mg dose of Rybelsus, a pill formulation of the drug semaglutide, processed with DehydraTECH both as a swallowable capsule and as an oral dissolvable tablet. The study is ...